Figure 3.

Evaluation of the neutralizing activity of several sarbecovirus broadly neutralizing mAbs and vaccine-elicited polyclonal antibodies

(A) Neutralization potency (50% inhibition concentration [IC₅₀]) of the mAbs S309, S2E12, S2X259, and S2H14 against VSV pseudotyped with either the wild-type (G614) or the E406W mutant spike protein. Non-neutralizing values are shown as 2 × 10⁴ ng/mL, the limit of detection of the assay, as indicated by a dotted line.

(B and C) Neutralization potency (50% inhibition dilution [ID₅₀]) of sera collected from individuals vaccinated with either Pfizer Cominarty (B) or Moderna’s mRNA-1273 (C) against VSV pseudotyped with SARS-CoV-2 wild-type (G614) or E406W spike. ID₅₀ values measured against the two pseudoviruses for each sample are connected by a line. The dotted line indicates the limit of detection of the assay.